

9th November 2022

The BSE Limited 1st floor, New Trading Ring Rotunda Building, P.J Towers Dalal Street, Mumbai - 400 001.	The National Stock Exchange of India Limited Exchange Plaza, 5 th Floor Plot No. C/1, G. Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.
Script Code: 500259	Script Code: LYKALABS

Dear Sir/ Madam,

Subject: Outcome of the Board Meeting held on 9th November 2022

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; we wish to inform you that the Board of Directors in its meeting held today i. e. 9th November 2022 *inter alia* considered and approved the following:

1. The Standalone and Consolidated Unaudited Financial Results for the quarter and the half year ended 30th September 2022

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following as Annexure-1:

The Unaudited Standalone and Consolidated Financial Results for the quarter and the half year ended 30th September 2022 along with the Limited Review Reports of the Auditors thereof.

The Board noted the performance of the Company during the Second Quarter ended 30th September 2022 as under:

Standalone Financial Result Summary:

(Rs. in Lakhs)

Particulars	Quarter ended 30 th September 2022	Quarter ended 30 th June, 2022	Quarter ended 30 th September, 2022
Revenue from Operation	2212.71	2187.84	6501.76
EBIDTA	576.99	660.39	4506.39
Profit After Tax	(39.64)	32.53	2981.32

Consolidated Financial Result Summary:

(Rs. in Lakhs)

Particulars	Quarter ended 30 th September 2022	Quarter ended 30 th June, 2022	Quarter ended 30 th September 2022
Revenue from Operation	2552.66	2749.20	7388.94
EBIDTA	621.82	701.98	4631.56
Profit After Tax	(38.38)	59.35	2843.22

2. Noting resignation of Mr. Piyush G. Hindia, Company Secretary and Compliance officer of the Company.

Mr. Piyush G. Hindia, Company Secretary & Compliance Officer of the Company has resigned. His resignation has been taken on record by the Board of Directors in its meeting held today.

Page 1 of 2

3. Appointment of Mr. Kishore P. Shah, as Company Secretary and Compliance Officer of the Company.

Pursuant to the recommendation of the Nomination and Remuneration Committee, Mr. Kishore P. Shah, a qualified Company Secretary, has been appointed as the Company Secretary with effect from 9th November 2022.

Mr. Kishore P. Shah will be also the Compliance Officer for the purpose of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Pursuant to SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, the details are provided in Annexure-II.

4. Appointment of Mr. Kishore P. Shah, as Nodal Officer under Investor Education and Protection Fund (IEPF) Rules, 2016.

Mr. Kishore P Shah will be also a Nodal Officer under the Investor Education and Protection Fund (IEPF) Rules, 2016 with effect from 9th November 2022.

5. The Board has considered acquisition of animal healthcare business from Agilis Healthcare Private Limited

Pursuant to SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, the details for the acquisition are provided in Annexure-III.

The Board Meeting commenced at 12 noon and concluded at 1:30 p.m.

Kindly take the above information on your record.


Thanking You,

Yours faithfully,
For Lyka Labs Limited

Kunal N. Gandhi
Managing Director & CEO
DIN: 01516156

Encl.: A/a.


Statement of Standalone Unaudited Financial Results for the Quarter / Half Year Ended 30th September, 2022						
Particulars	(₹ in lakh)					
	Quarter Ended			Half Year Ended		Year Ended
	30th September, 2022 (Unaudited)	30th June, 2022 (Unaudited)	30th September, 2021 (Unaudited)	30th September, 2022 (Unaudited)	30th September, 2021 (Unaudited)	31st March, 2022 (Audited)
I. Revenue						
Revenue from Operations	2,212.71	2,187.84	6,501.76	4,400.55	10,848.36	16,434.88
Other Income	103.90	68.39	85.58	172.29	138.69	271.98
II. Total Income	2,316.61	2,256.23	6,587.34	4,572.84	10,987.05	16,706.86
III. Expenses						
(a) Cost of Materials Consumed	581.64	683.84	802.32	1,265.48	1,474.79	2,693.80
(b) Purchase of Stock in trade	266.82	194.06	71.95	460.87	75.62	432.83
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade.	14.84	(65.06)	22.69	(50.22)	(78.24)	(40.43)
(d) Employee benefits expense	449.99	370.84	415.60	820.83	814.97	1,621.96
(e) Finance Costs	291.45	280.06	552.72	571.51	1,241.69	1,992.13
(f) Depreciation and amortisation expense	345.50	341.36	208.79	686.86	413.94	1,538.87
(g) Other expenses	426.33	412.16	768.39	838.49	1,159.83	1,976.81
Total Expenses	2,376.57	2,217.26	2,842.46	4,593.82	5,102.60	10,215.97
IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)	(59.96)	38.97	3,744.88	(20.98)	5,884.45	6,490.89
V. Exceptional Items (Net)	13.72	0.08	204.31	13.80	204.31	466.83
VI. Profit / (Loss) before Tax	(73.68)	38.89	3,540.57	(34.78)	5,680.14	6,024.06
VII. Deferred Tax	(34.04)	6.06	559.32	(27.98)	734.30	2,033.83
VIII. Net Profit / (Loss) after Tax	(39.64)	32.83	2,981.25	(6.80)	4,945.84	3,990.23
IX. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)	(3.18)	(3.18)	(3.82)	(6.35)	(12.64)	12.69
X. Total Comprehensive Income / (Loss)	(42.82)	29.65	2,977.43	(13.15)	4,933.20	4,002.92
Paid up Equity Share Capital (Face value ₹ 10/- each)	2,869.00	2,869.00	2,869.00	2,869.00	2,869.00	2,869.00
Other Equity						1,574.85
XI. Basic and diluted earnings per share	(0.15)	0.11	10.38	(0.04)	17.22	13.87




Unaudited Statement of Assets & Liabilities as at 30th September, 2022

(₹ in lakh)

Particulars	As at 30th September, 2022	As at 31st March, 2022
ASSETS		
1 Non-Current Assets		
(a) Property, Plant and Equipment	5,805.49	6,717.78
(b) Capital Work- In- Progress	1,416.74	1,623.49
(c) Intangible assets	1,919.83	2,293.50
(d) Intangible assets under development	104.04	150.82
	9,246.10	10,785.59
(e) Financial Assets		
(i) Investments	3,240.30	3,240.30
(ii) Other Financial Assets	1,469.75	1,433.01
(f) Other Non Current Assets	123.14	131.63
(g) Non Current Tax Assets	501.68	469.74
	5,334.87	5,274.68
2 Current Assets		
(a) Inventories	700.82	818.44
(b) Financial Assets		
(i) Investments	0.81	0.80
(ii) Trade Receivables	1,911.74	1,758.84
(iii) Cash and Cash Equivalents	1,510.05	1,538.31
(iv) Loans	193.24	3.71
(v) Other Financial Assets	294.67	177.46
(c) Other Current Assets	457.13	493.42
(d) Assets Held for Sale	954.07	-
	6,022.53	4,790.96
Total Assets	20,603.50	20,851.24
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	2,869.00	2,869.00
(b) Other Equity	1,561.71	1,574.85
	4,430.71	4,443.85
LIABILITIES		
1 Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	10,950.26	6,162.74
(ii) Other Financial Liabilities	93.14	221.20
(b) Provisions	239.21	244.15
(c) Deferred Tax Liabilities (net)	383.78	411.76
	11,666.39	7,039.85
2 Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,601.79	6,658.75
(ii) Lease Liabilities	9.15	28.76
(iii) Trade Payable		
- Micro and Small Enterprise	290.05	445.98
- Other than Micro and Small Enterprise	714.79	422.28
(iv) Other Financial Liabilities	967.63	1,116.60
(b) Other Current Liabilities	819.87	593.44
(c) Provisions	103.12	101.73
	4,506.40	9,367.54
Total Equity and Liabilities	20,603.50	20,851.24



Lyka Labs Limited			
Unaudited Cash Flow Statement for the Half Year Ended 30th September, 2022			
(₹ in lakh)			
Particulars	For the Half Year Ended 30th September, 2022		For the Half Year Ended 30th September, 2021
A. Cash Flow from Operating Activities			
Profit / (Loss) for the year before tax		(34.78)	5,680.14
Adjusted for			
Depreciation	686.86		413.94
Interest Income	(89.10)		(28.08)
Finance Cost	571.51		1,241.69
Provision for Doubtful Trade Receivables, Advances, Employee Benefits	35.83		7.43
Exchange rate fluctuation	(54.03)		(18.03)
Exceptional Items	2.08		115.27
Return on Investment	(0.01)		
		1,153.14	1,732.22
Operating profit before working capital change		1,118.36	7,412.36
Changes in Working Capital :			
(Increase) / Decrease in Other Non-Current Financial Assets	(38.82)		(138.03)
(Increase) / Decrease in Other Non-Current Assets	8.49		30.13
(Increase) / Decrease in Inventories	117.62		(393.34)
(Increase) / Decrease in Trade and other receivables	(106.81)		(750.35)
(Increase) / Decrease in Other Current Financial Assets	(117.21)		(43.91)
(Increase) / Decrease in Other Current Assets	36.29		(151.25)
(Increase) / Decrease in Current Loans	(189.53)		(29.95)
Increase / (Decrease) in Other Non-Current Financial Liabilities	(3.64)		1.37
Increase / (Decrease) in Non-Current Provisions	(4.94)		(53.87)
Increase / (Decrease) in Trade Payables	136.58		(45.15)
Increase / (Decrease) in Other Current Financial Liabilities	(135.74)		330.39
Increase / (Decrease) in Other Current Liabilities	226.43		255.82
Increase / (Decrease) in Current Provisions	(32.85)		(28.22)
		(104.13)	(1,016.36)
Cash generated from operations		1,014.23	6,396.00
Net Income Tax Payment	(31.94)	(31.94)	3.23
Net cashflow from operating activities (A)		982.29	6,399.23
B. Cashflow for Investing activities			
Purchase of fixed assets	(101.46)		(452.93)
Interest Received	89.10		28.08
Net cash used in Investing activities (B)		(12.36)	(424.85)
C. Cashflow from Financing activities			
Proceed from / (Repayment) of Non Current Borrowings Net	(25.56)		(4,685.98)
Proceed from / (Repayment) of Current Borrowings Net	(387.90)		400.40
Interest Paid	(584.74)		(1,288.88)
Net cash used in Financing activities (C)		(998.20)	(5,574.46)
Net increase / (decrease) in cash and cash equivalents (A+B+C)		(28.27)	399.92
Cash and Cash Equivalents at the beginning of the year/period			
Cash and Cash Equivalents		28.03	11.66
Earmarked Balances		1,510.29	641.18
		1,538.32	652.84
Cash and Cash Equivalents at the end of the year/period			
Cash and Cash Equivalents		29.45	11.02
Earmarked Balances		1,480.60	1,041.74
		1,510.05	1,052.76







Notes:

1. The above unaudited standalone financial results as reviewed by the Audit Committee at their meeting and have been approved and taken on record at the meeting of the Board of Directors held on 9th November 2022.
2. The Company operates in one reportable business segment i.e. "Pharmaceuticals".
3. The figures for previous year/ period have been regrouped / rearranged wherever considered necessary.
4. The statutory auditors of Lyka Labs Limited have expressed an unqualified opinion on the unaudited standalone financials results for the quarter ended 30th September 2022.

Mumbai
9th November 2022



For LYKALABS LIMITED


Kunal N. Gandhi (DIN 01516156)
(Managing Director)





D. KOTHARY & CO.


Chartered Accountants


Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Lyka Labs Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Lyka Labs Limited (the "Company") for the quarter ended September 30, 2022 and year to date from April 1, 2022 to September 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Regn No. 105335W


Mehul N. Patel
(Partner)
Membership No. 132650




UDIN: 22132650BCPMWA2475

Place: Mumbai
Date: 9th November, 2022


Statement of Consolidated Unaudited Financial Results for the Quarter / Half Year Ended 30th September, 2022

Particulars	(₹ in lakh)					
	Quarter Ended			Half Year Ended		Year Ended
	30th September, 2022 (Unaudited)	30th June, 2022 (Unaudited)	30th September, 2021 (Unaudited)	30th September, 2022 (Unaudited)	30th September, 2021 (Unaudited)	31st March, 2022 (Audited)
I. Revenue						
Revenue from Operations	2,552.66	2,749.20	7,388.94	5,301.86	12,332.62	19,408.49
Other Income	118.97	71.78	68.53	190.75	115.54	209.42
II. Total Income	2,671.63	2,820.98	7,457.47	5,492.61	12,448.16	19,617.91
III. Expenses						
(a) Cost of Materials Consumed	581.64	683.84	802.32	1,265.48	1,474.79	2,693.80
(b) Purchase of Stock in trade	502.86	644.78	692.79	1,147.64	1,232.10	2,644.56
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	15.02	(65.25)	49.52	(50.23)	(77.49)	(41.04)
(d) Employee benefits expense	477.96	401.24	466.96	879.20	913.74	1,805.76
(e) Finance Costs	303.21	290.71	557.35	593.92	1,249.97	2,012.88
(f) Depreciation and amortisation expense	362.11	358.62	351.69	720.73	564.78	1,734.94
(g) Other expenses	472.33	454.39	814.32	926.72	1,236.65	2,190.43
Total Expenses	2,715.13	2,768.33	3,734.95	5,483.46	6,594.54	13,041.33
IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)	(43.50)	52.65	3,722.52	9.15	5,853.62	6,576.58
V. Exceptional Items (Net)	20.68	(23.43)	389.36	(2.75)	389.36	651.88
VI. Profit / (Loss) before Tax	(64.18)	76.08	3,333.16	11.90	5,464.26	5,924.70
VII. Non Controlling Interest	4.15	11.20	(75.79)	15.35	(82.67)	(55.65)
VIII. Profit / (Loss) before Tax	(68.33)	64.88	3,408.95	(3.45)	5,546.93	5,980.35
IX. Deferred Tax	(29.95)	5.35	565.63	(24.60)	748.54	2,057.94
Tax relating to earlier years						22.43
X. Net Profit / (Loss) after Tax	(38.38)	59.53	2,843.32	21.15	4,798.39	3,899.98
XI. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)	(3.18)	(3.18)	(3.82)	(6.35)	(12.64)	14.01
XII. Total Comprehensive Income / (Loss)	(41.56)	56.35	2,839.50	14.80	4,785.75	3,913.99
XIII. Paid up Equity Share Capital (Face value Rs.10/- each)	2,869.00	2,869.00	2,869.00	2,869.00	2,869.00	2,869.00
Other Equity						(1,535.15)
XIV. Basic and diluted earnings per share	(0.14)	0.20	9.90	0.05	16.71	13.57




Unaudited Consolidated Statement of Assets & Liabilities as at 30th September, 2022

Particulars	(₹ in lakh)	
	As at 30th September, 2022	As at 31st March, 2022
ASSETS		
1 Non-Current Assets		
(a) Property, Plant and Equipment	6,008.04	6,936.36
(b) Capital Work- In- Progress	1,416.74	1,623.49
(c) Intangible assets	2,067.68	2,459.17
(d) Intangible assets under development	104.04	150.82
	9,596.50	11,169.84
(e) Financial Assets		
(i) Investments	0.89	0.89
(ii) Other Financial Assets	1,473.02	1,436.28
(f) Other Non Current Assets	123.14	131.63
(g) Non Current Tax Assets	634.88	602.98
	2,231.93	2,171.78
2 Current Assets		
(a) Inventories	702.19	819.81
(b) Financial Assets		
(i) Investments	0.81	0.80
(ii) Trade Receivables	2,130.16	1,845.27
(iii) Cash and Cash Equivalents	1,659.63	1,705.05
(iv) Loans	6.47	4.45
(v) Other Financial Assets	292.09	176.43
(c) Other Current Assets	625.08	668.01
(d) Assets Held for Sale	954.07	-
	6,370.50	5,219.82
Total Assets	18,198.94	18,561.44
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	2,869.00	2,869.00
(b) Other Equity	(1,520.36)	(1,535.15)
Equity attributable to owners of the company	1,348.64	1,333.85
(c) Non - Controlling Interest	30.60	15.25
	1,379.24	1,349.10
LIABILITIES		
1 Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	11,003.05	6,248.60
(ii) Other Financial Liabilities	100.19	258.26
(b) Provisions	340.97	346.88
(c) Deferred Tax Liabilities (net)	398.74	423.34
	11,842.96	7,277.08
2 Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,960.54	6,711.86
(ii) Lease Liabilities	9.15	28.76
(iii) Trade Payables due to :		
- Micro and Small Enterprise	444.98	557.42
- Other than Micro and Small Enterprise	739.61	642.12
(iv) Other Financial Liabilities	1,044.29	1,205.61
(b) Other Current Liabilities	668.87	684.81
(c) Provisions	109.31	104.69
	4,976.74	9,935.27
Total Equity and Liabilities	18,198.94	18,561.44



Lyka Labs Limited			
Unaudited Consolidated Cash Flow Statement for the Half Year Ended 30th September, 2022			
(₹ in lakh)			
Particulars	For the Half Year Ended 30th September, 2022		For the Half Year Ended 30th September, 2021
A. Cash Flow from Operating Activities			
Profit / (Loss) for the year before tax		11.90	5,464.25
Adjusted for			
Depreciation	720.73		564.78
Interest Income	(89.15)		(29.85)
Finance Cost	593.92		1,249.97
Provision for Doubtful Trade Receivables, Advances, Employee Benefits	17.96		18.42
Exchange rate fluctuation	(59.38)		(30.37)
Exceptional Items	(34.78)		115.27
Return on Investment	(0.01)		
		1,149.29	1,888.22
Operating profit before working capital change		1,161.19	7,352.47
Changes in Working Capital :			
(Increase) / Decrease in Other Non-Current Financial Assets	(1.96)		(137.53)
(Increase) / Decrease in Other Non-Current Assets	8.49		31.03
(Increase) / Decrease in Inventories	117.62		(392.58)
(Increase) / Decrease in Trade and other receivables	(209.95)		(663.58)
(Increase) / Decrease in Other Current Financial Assets	(115.66)		(42.45)
(Increase) / Decrease in Other Current Assets	42.93		52.63
(Increase) / Decrease in Non-Current Loans	-		10.88
(Increase) / Decrease in Current Loans	(2.02)		0.00
Increase / (Decrease) in Other Non-Current Financial Liabilities	(33.64)		1.37
Increase / (Decrease) in Non-Current Provisions	(5.91)		(51.47)
Increase / (Decrease) in Trade Payables	(14.95)		(219.19)
Increase / (Decrease) in Other Current Financial Liabilities	(122.02)		338.41
Increase / (Decrease) in Other Current Liabilities	(15.94)		261.38
Increase / (Decrease) in Current Provisions	(35.25)		(30.62)
		(388.26)	(841.72)
Cash generated from operations		772.93	6,510.75
Net Income Tax Payment	(31.91)	(31.91)	(11.47)
Net cashflow from operating activities (A)		741.02	6,499.28
B. Cashflow for Investing activities			
Purchase of fixed assets	(101.46)		(612.19)
Interest Received	89.15		29.85
Net cash used in Investing activities (B)		(12.31)	(582.34)
C. Cashflow from Financing activities			
Proceed from / (Repayment) of Non Current Borrowings Net	(39.02)		(4,594.40)
Proceed from / (Repayment) of Current Borrowings Net	(101.87)		411.86
Interest Paid	(633.22)		(1,329.90)
Net cash used in Financing activities (C)		(774.11)	(5,512.44)
Net increase / (decrease) in cash and cash equivalents (A+B+C)		(45.40)	404.50
Cash and Cash Equivalents at the beginning of the year/period			
Cash and Cash Equivalents		134.66	23.59
Earmarked Balances		1,570.39	691.77
		1,705.05	715.36
Cash and Cash Equivalents at the end of the year/period			
Cash and Cash Equivalents		43.93	17.53
Earmarked Balances		1,615.70	1,102.34
		1,659.63	1,119.86







Notes:

1. The above unaudited consolidated financial results as reviewed by the Audit Committee at their meeting and have been approved and taken on record at the meeting of the Board of Directors held 9th November 2022.
2. The Group operates in one reportable business segment i.e. "Pharmaceuticals".
3. The figures for previous year have been regrouped / rearranged wherever considered necessary.
4. The statutory auditors of Lyka Labs Limited have expressed an unqualified opinion on the unaudited consolidated financials results for the quarter ended 30th September 2022.

For LYKA LABS LIMITED




Kunal N. Gandhi (DIN 01516156)

(Managing Director)

Mumbai

9th November, 2022





D. KOTHARY & CO.

Chartered Accountants

Independent Auditor's Review Report on the Quarterly and Year-to-Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Lyka Labs Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Lyka Labs Limited ("the Parent"), which includes its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended September 30, 2022 and year-to-date from April 1, 2022 to September 30, 2022 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:


Parent

- i) Lyka Labs Limited

Subsidiaries

- i) Lyka BDR International Limited
- ii) Lyka Exports Limited

5. The accompanying statement includes the interim financial results and other financial information in respect of two subsidiaries, whose interim financial results/information reflects total assets of Rs. 1,391.29 lakhs as at September 30, 2022, total revenues of Rs. 551.37 lakhs and Rs. 1,270.91 lakhs, total net profit after tax of Rs. 5.37 lakhs and Rs. 43.26 lakhs, for the quarter ended September 30, 2022 and year-to-date from April 1, 2022 to September 30, 2022 respectively, and net cash outflows of Rs. 17.16 lakhs as at September 30, 2022, which have been reviewed by us.






D. KOTHARY & CO.

Chartered Accountants

6. Based on our review conducted and procedures performed as stated in para 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Registration No. 105335W


Mehdi N. Patel
Partner
Membership No. 132650



UDIN: 22132650BCPNEG12515.

Place: Mumbai
Date: 9th November, 2022

Annexure-II

Details under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 read along SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015

Change in Company Secretary and Compliance Officer of the Company

Sr. No	Details of events that need to be provided	Details of Change	
		Mr. Piyush G. Hindia	Mr. Kishore P. Shah
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Resignation	Appointment
2.	Date of appointment/cessation	9th November 2022	9th November 2022
3.	Brief profile (in case of appointment)	Not applicable	Mr. Kishore P. Shah has dual qualified Company Secretary with more than 20 years of experience in various companies, including listed companies.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable	Not applicable

Annexure III

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name of the target entity, details in brief such as size, turnover etc.	Animal Healthcare Business of Agilis Healthcare Private Limited on Slump Sale basis. Sales for the FY 2022 is Rs. 470 Lacs (approx.)
b) Whether the acquisition would fall within related party transaction(s) and whether the Promoter/ Promoter Group/ Group Companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length".	No
c) Industry to which the entity being acquired belongs	Animal Healthcare Products
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Business Expansion
e) Brief details of any governmental or regulatory approvals required for the acquisition	No
f) Indicative time period for completion of the acquisition	On or before 31st March, 2023, subject to completion of closing conditions.
g) Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
h) Cost of acquisition or the price at which the shares are acquired	Up to Rs. 3.5 Crores
i) Percentage of shareholding / control acquired and / or number of shares acquired	Not applicable
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Brief background: Agilis Healthcare Private Limited is a Mumbai based company, incorporated in 2017. The company is in the business of animal healthcare, having 50+ employees. The company is marketing veterinary medicines and feed supplement products in India</p> <p>Line of business: Animal Healthcare Products</p> <p>Date of incorporation 14th November, 2017</p> <p>Turnover of last 3 financial years: FY 2020 -Rs. 432.73 Lacs FY 2021 -Rs. 558.12 Lacs FY 2022 -Rs. 469.73 Lacs</p> <p>Country in which the acquired entity has presence:India</p>